Search | Clinical Trials Finder

Conditions: Sturge-Weber Syndrome (SWS), Glaucoma, Glaucoma Congenital, Ocular Hypertension
Interventions: QLS-101ophthalmic solution 1%, QLS-101ophthalmic solution 2%; Drug
Lead sponsor: Qlaris Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Eye Diseases
Interventions: Anecortave Acetate Sterile Suspension, 6 mg/mL, Anecortave Acetate Suspension Depot, 30 mg/mL, Anecortave Acetate Sterile Suspension, 60 mg/mL, Anecortave Acetate Vehicle; Drug · Other
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 5
States / cities: Jacksonville, Florida • Miami, Florida • Detroit, Michigan + 2 more

Conditions: Primary Open Angle Glaucoma, Ocular Hypertension
Interventions: QLS-101, Timolol Maleate; Drug
Lead sponsor: Qlaris Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Albany, Georgia

Conditions: Open Angle Glaucoma, Ocular Hypertension, Glaucoma, Open Angle, Pseudo-exfoliative, Pigment Dispersion Syndrome, Glaucoma
Interventions: Selective Laser Trabeculoplasty, Neodymium:Yttrium Aluminum Garnet (YAG) laser; Procedure · Device
Lead sponsor: Temple University; Other
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Wilmington, Delaware • Thorndale, Pennsylvania

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: AR-17043 Ophthalmic Solution, PG043 Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution, Netarsudil 0.02% Ophthalmic Solution, Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution, AR-17043 Vehicle; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 12
States / cities: Garden Grove, California • Inglewood, California • Newport Beach, California + 9 more

Conditions: Glaucoma
Interventions: Tonometer; Device
Lead sponsor: Topcon Corporation; Industry
Eligibility: 22 Years and older
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 2
States / cities: La Mesa, California • Chicago, Illinois

Conditions: Open-Angle Glaucoma
Interventions: Blood Collection Only; Other
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Glaucoma, Ocular Hypertension
Interventions: Latanoprost 0.005%, AR-12286 Ophthalmic Solution 0.5%, Timolol maleate ophthalmic solution 0.5%; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 15
States / cities: New Haven, Connecticut • Roswell, Georgia • Shawnee Mission, Kansas + 11 more

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: AR-13324 Ophthalmic Solution 0.02%, Timolol Maleate Ophthalmic Solution 0.5% BID, Placebo; Drug · Other
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 708 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Bedminster, New Jersey

Conditions: Primary Open Angle Glaucoma
Interventions: Rocklatan (netarsudil 0.02% and latanoprost 0.005%), Systane; Drug
Lead sponsor: Center for Sight Las Vegas; Other
Eligibility: 40 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Glaucoma
Interventions: Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 21
States / cities: Mission Hills, California • Newport Beach, California • Pasadena, California + 17 more

Conditions: Ocular Hypertension, Open Angle Glaucoma
Interventions: AR-13324 Ophthalmic Solution 0.01%, AR-13324 Ophthalmic Solution 0.02%, Latanoprost ophthalmic solution 0.005%; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 22
States / cities: Artesia, California • Inglewood, California • Newport Beach, California + 19 more

Conditions: Glaucoma, Ocular Hypertension
Interventions: latanoprost 0.005% ophthalmic solution, Travoprost 004% sterile ophthalmic solution, Bimatoprost .03% sterile ophthalmic solution; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002
U.S. locations: 40
States / cities: Bellflower, California • Inglewood, California • San Diego, California + 31 more

Conditions: Glaucoma
Interventions: AR-102 0.003% Ophthalmic Solution, AR-102 0.005% Ophthalmic Solution, AR-102 0.01% Ophthalmic Solution, AR-102 0.03% Ophthalmic Solution, AR-102 Vehicle Ophthalmic Solution; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 8
States / cities: Pasadena, California • Petaluma, California • Brooksville, Florida + 5 more

Conditions: Cataract
Interventions: Cataract surgery at high IOP, Cataract surgery at low IOP; Procedure
Lead sponsor: Wolfe Eye Clinic; Other
Eligibility: 55 Years to 95 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Hiawatha, Iowa

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 1,099 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Murfreesboro, Tennessee

Conditions: Thyroid Eye Disease, Ocular Hypertension, Glaucoma
Interventions: Prostaglandin Analog, Timolol; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Stanford, California

Conditions: Intraocular Pressure
Interventions: Adjusting intraocular pressure (IOP) settings; Device
Lead sponsor: Research Insight LLC; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Laguna Hills, California

Conditions: Nuclear Cataract
Interventions: High IOP, Low IOP; Other
Lead sponsor: Matthew Rauen; Other
Eligibility: Not listed
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: West Des Moines, Iowa

Conditions: Glaucoma
Interventions: Brinzolamide 1% ophthalmic solution (Azopt), Placebo eye drops, Latanoprost 0.005% ophthalmic solution (Xalatan); Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 35 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Elevated Intraocular Pressure (IOP)
Interventions: Photobionic IOP Tonometer (PIB); Device
Lead sponsor: EyeCBetter Corporation; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: La Quinta, California

Conditions: Primary Open Angle Glaucoma
Interventions: Not listed
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Ocular Hypertension, Glaucoma
Interventions: AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.02% BID, Timolol maleate Ophthalmic Solution 0.5% BID, Placebo; Drug · Other
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 19 Years to 99 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Bedminster, New Jersey

Conditions: Microvascular Disease, Retinal Disease
Interventions: XyCAM CRE Imaging; Device
Lead sponsor: Stuart Terry Eye Associates; Other
Eligibility: 21 Years to 100 Years
Enrollment: 350 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101

Anecortave Acetate for Treatment of Steroid Induced Intraocular Pressure (IOP) Elevation

Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).

180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma

Next Generation Rocklatan

TRK-3 Conformance to Standards for Tonometers

Collection of Blood Specimens From Patients in AL-3789 Studies for Elevated Intraocular Pressure (IOP)

AR-12286 in Combination With Latanoprost

Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension

Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery)

Rocklatan® Evaluation

Study Comparing the Safety and Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure

Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US

Ocular Hypotensive Efficacy of AR-102

Physiologic Phacofluidics: Ghost Protocol

Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)

The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.

2311 TURGOR Study -Surgical Efficiency and Postoperative Corneal Clarity With Near Physiologic vs High IOP Settings

Phacoemulsification at High IOP and Physiologic IOP: Impact on Anterior and Posterior Segment Physiology

A Comparison of Azopt Versus Placebo Added to Xalatan in Patients With Elevated Intraocular Pressure (IOP) on a Prostaglandin

Clinical Investigation of Eye C Better's Photobionic Intraocular Pressure Biomonitor Tonometer

STudy to Assess Rapid Disease Progression by Clinical and Genetic Factors In Glaucoma patientS That Are High Risk

Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Collecting Data on Retinal Blood Blood Flow and Blood Vessel Shape/Appearance Using an Investigational Device, XyCAM CRE, and to Then Compare Those Images With Images Collected From a Patient's Routine Clinical Examination.